|
|
|
|
|
|
|
|
Patient deaths halt study of new approach to treating cancer
With the two new deaths, Juno faces tough questions about the safety of its therapy, called JCAR015. And the FDA will likely come under fire for allowing the company to get back to work just days after the first clinical hold.JUNO: https://www.junotherapeutics.com/pipeline/clinical/
MUC16
JCAR020 | NCT02498912 | A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
clinicaltrials.gov:
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Verified November 2016 by Memorial Sloan Kettering Cancer CenterSponsor:Memorial Sloan Kettering Cancer CenterCollaborators:Stanford UniversityJuno Therapeutics, Inc.Information provided by (Responsible Party):Memorial Sloan Kettering Cancer Center
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.